Oral Semaglutide (Rybelsus)
GLP-1 Receptor Agonist (Oral)approvedAlso known as: Rybelsus, Oral GLP-1, Semaglutide Tablets
An oral formulation of semaglutide co-formulated with the absorption enhancer SNAC, enabling GLP-1 receptor agonist therapy via daily tablet rather than weekly injection.
Overview
Oral semaglutide (brand name Rybelsus) is the first GLP-1 receptor agonist available in oral tablet form, approved by the FDA in 2019 for type 2 diabetes. It uses sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) as an absorption enhancer that protects semaglutide from enzymatic degradation in the stomach and facilitates transcellular absorption. While chemically identical to injectable semaglutide (Ozempic/Wegovy), the oral formulation requires daily dosing and higher absolute doses due to low oral bioavailability (~1%). It offers the convenience of oral administration for patients who prefer not to inject, though it requires strict fasting conditions for proper absorption.
Mechanism of Action
Oral semaglutide activates GLP-1 receptors throughout the body: (1) Pancreatic beta cells increase glucose-dependent insulin secretion; (2) Hypothalamic appetite centers reduce hunger and caloric intake; (3) Gastric motility is slowed, promoting satiety; (4) Glucagon secretion is suppressed in a glucose-dependent manner; (5) The SNAC absorption enhancer creates a localized pH increase in the stomach, protecting the peptide and enabling transient transcellular absorption across the gastric epithelium.
Molecular Formula
C187H291N45O59
Molecular Weight
4113.58 g/mol
Sequence
Modified GLP-1 analog with C-18 fatty diacid chain (same as injectable semaglutide)
Dosage Protocols
Dose Range
3mg – 14mg
Frequency
Once daily
Route
oral
Cycle Length
Ongoing
Start at 3mg for 30 days, increase to 7mg, then optionally to 14mg. Must be taken on empty stomach with no more than 4oz of plain water, then fast for 30 minutes.
Source: FDA prescribing information
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
7mg or 14mg tablets
Last Updated
2026-02
Brand Rybelsus. List ~$900-1,000/mo. Insurance/coupons: $200-500. First oral GLP-1. Must take on empty stomach.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Nausea | moderate |
| Diarrhea | mild |
| Decreased appetite | mild |
| Vomiting | moderate |
| Abdominal pain | mild |
Pros & Cons
First and only oral GLP-1 receptor agonist, eliminating the need for injections
FDA-approved with robust clinical trial data supporting efficacy and safety
Significant HbA1c reduction and modest weight loss in clinical trials
Cardiovascular safety demonstrated in the PIONEER 6 trial
Strict dosing requirements: must fast 30 min before and after taking with minimal water
Very low oral bioavailability (~1%) requires much higher doses than injectable form
Daily dosing vs weekly for injectable semaglutide may reduce adherence
Less weight loss compared to injectable semaglutide at currently approved doses
Research Studies
🩸 Blood Work
HbA1c
Baseline blood sugar levels — essential for GLP-1 therapy
Fasting Blood Glucose
Monitor for hypoglycemia risk
Lipid Panel
Baseline cholesterol and triglycerides
Kidney Function (BMP/CMP)
GLP-1s can affect renal function
Thyroid Panel (TSH, T3, T4)
Thyroid C-cell tumor warnings apply to all semaglutide formulations
Liver Function Panel (AST/ALT)
Baseline liver health
Same bloodwork requirements as injectable semaglutide. Oral formulation has identical mechanism and risk profile.
Legal Status
FDA-approved as Rybelsus for type 2 diabetes (2019). Prescription-only medication. Available in 3mg, 7mg, and 14mg tablets.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.